Enliven的ELVN-001在具有非典型融合转录物的患者中显示出抗慢性粒细胞白血病活性;将在ASH 2025年年会上展示正在进行的ELVN-001针对慢性粒细胞白血病患者亚群的ENABLE 1a/1b期临床试验的数据

ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcripts

Growing unmet need for patients with atypical transcript e13a3, which is resistant to TKIs targeting the myristoyl pocket

BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present data from the ongoing ENABLE Phase 1a/1b clinical trial of ELVN-001 on a subset of chronic myeloid leukemia (CML) patients, specifically in patients with atypical fusion transcripts, at the 67th Annual American Society of Hematology (ASH) 2025 Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.